Cleveland Clinic Abu Dhabi launches ‘Aila,’ an AI platform billed as the world’s first clinical AI scientist

Cleveland Clinic Abu Dhabi has partnered with biotech AI company Owkin to launch a clinical artificial intelligence platform called Aila. The hospital is calling it the world's first clinical AI scientist, a bold claim that signals just how seriously the institution is betting on AI to change how doctors work.

The platform is built to do something doctors have long wanted: take vast amounts of fragmented clinical data and make it quickly searchable and useful in the middle of a patient consultation. Through a natural-language interface, physicians can ask questions and get answers that would otherwise take days of manual analysis.

The initial rollout focuses on prostate cancer, pulling together electronic health records, physician notes, pathology reports, and medical imaging into a single system a doctor can actually talk to.

How does it work?

Aila runs on Owkin's agentic K Pro platform, which is purpose-built for biology and medical research. The core idea is straightforward: instead of siloed data sitting in separate systems, Aila connects those sources into one queryable layer.

Clinicians interact with it using plain-language questions, no technical queries required. The system then reasons across the connected data and returns insights in real time. It is also designed to keep learning as it processes more data over time.

The longer-term roadmap is ambitious:

• Expansion beyond prostate cancer into other medical specialties
• Support for more complex data types, including genomics and multi-omics data
• Integration into large-scale precision medicine programs

All of this runs on infrastructure supported by the UAE's existing AI framework, which gives the platform room to scale.

Why does it matter?

The core problem Aila is trying to solve is one that frustrates clinicians everywhere. Patient data exists in abundance, but it is scattered across systems that do not talk to each other. A doctor trying to make a decision often has to piece together records manually, or simply work without the full picture.

If Aila works as described, it could meaningfully cut the time between data and decision. In cancer care especially, where treatment paths depend on combining imaging, pathology, genetics, and clinical history, that speed matters.

There is also a research angle. By connecting datasets at scale and making them queryable, the platform could help identify patterns across large patient populations that would be invisible to any individual physician reviewing individual cases.

The context

This launch fits into a much broader push by hospitals and health systems worldwide to move AI out of the lab and into actual clinical practice. Most AI health tools so far have focused on narrow tasks: reading a scan, flagging an anomaly, predicting a readmission. A platform designed to reason across multiple data types simultaneously is a step up in ambition.

Owkin has been building in this direction for several years, working with hospitals in Europe and the US on federated learning and AI-driven drug discovery. The Abu Dhabi collaboration is its most public deployment of an integrated clinical AI system.

The UAE has positioned itself aggressively as a hub for AI development, with national strategies and infrastructure investments designed to attract exactly this kind of project. Cleveland Clinic Abu Dhabi, a branch of the US-based Cleveland Clinic, brings the clinical credibility and patient data volume needed to make the platform viable from day one.

Whether Aila lives up to the 'world's first' billing will depend on outcomes data. But as a signal of where hospital AI is heading, the launch is hard to ignore.